Uremic Striatopallidal Syndrome Manifesting As Acute Onset Chorea
Objective: The relationship between movement disorders and renal diseases is complex and multifaceted. Movement disorders can occur as manifestations of azotemia (uremic encephalopathy, uremic striatopallidal…Advancing regulatory endorsed drug development tools in alignment with emerging biology: The Critical Path for Parkinson’s Consortium
Objective: To advance the regulatory maturity of drug development tools to support the newly proposed integrated staging of Neuronal Synuclein Disease (NSD-ISS) with focus on…Tremulous Machado-Joseph Disease
Objective: To describe a case of spinocerebellar ataxia type 3 (SCA3) presenting with tremor. Background: Tremor is not a frequent manifestation in SCA3, especially as…Imaging the Nigrostriatal Pathway in Patients with Idiopathic Normal Pressure Hydrocephalus and Parkinsonism
Objective: To investigate the nigrostriatal pathway in iNPH patients with clinical parkinsonism, employing dopaminergic transporter (DAT) and nigrosome imaging. Background: Patients with idiopathic Normal Pressure…Brain first-body first: is the dat-scan useful?
Objective: The purpose of this study is to evaluate possible differences in the DAT-SCAN ratios in patients with and without dysautonomia and RBD at diagnosis.…Premenstrual worsening of UPDRS motor scale in women affected by Parkinson’s Disease
Objective: The role of estrogen in dopaminergic pathways and the premenstrual worsening of parkinsonian symptoms. Background: Female sex hormones, during the menstrual cycle, could influence…Asymmetric and profound nigrostriatal dopaminergic dysfunction in Parkinson’s disease with preceding REM sleep behavior disorders
Objective: To investigate the differences in the pattern of nigrostriatal and pontine monoaminergic degeneration patients with de novo Parkinson's disease (PD), stratified by the presence…Evoking Parkinsonism in Mice by a Pharmacological Approach Combined with Targeted Viral-based Manipulations of Neuronal Ensembles
Objective: We implement a pharmacological approach for eliciting dopamine deprivation using transient blockage of dopamine signaling to replicate core parkinsonian motor symptoms. Background: Parkinson’s disease…Investigating the use of DAT-SPECT as an enrichment biomarker to determine eligibility for the phase 2 clinical trial PASADENA
Objective: Evaluate dopaminergic imaging DAT-SPECT as an enrichment strategy to avoid inclusion of participants with scans without evidence of dopaminergic deficit (SWEDD) in a Phase…Correlation between 3 Tesla Brain MRI Nigrosome-1 imaging and SPECT 123I-Ioflupane in parkinsonian disorders
Objective: To correlate nigrosome-1 (NG1) imaging and SPECT 123I-Ioflopane findings to determine the feasibility and diagnostic value of NG1 imaging in a real-world clinical setting.…
- 1
- 2
- 3
- …
- 5
- Next Page »